BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform...
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.059 | 12.2661122661 | 0.481 | 0.926 | 0.48 | 1087237 | 0.75772694 | CS |
4 | -0.075 | -12.1951219512 | 0.615 | 0.926 | 0.38 | 339971 | 0.7016984 | CS |
12 | 0.182 | 50.8379888268 | 0.358 | 0.926 | 0.31 | 477048 | 0.61177713 | CS |
26 | -1.79 | -76.8240343348 | 2.33 | 2.33 | 0.185 | 520028 | 0.48930049 | CS |
52 | -2.42 | -81.7567567568 | 2.96 | 3.16 | 0.185 | 461041 | 0.5001947 | CS |
156 | -2.42 | -81.7567567568 | 2.96 | 3.16 | 0.185 | 461041 | 0.5001947 | CS |
260 | -2.42 | -81.7567567568 | 2.96 | 3.16 | 0.185 | 461041 | 0.5001947 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約